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Abstract
Fabry disease is a X-linked lysosomal storage disorder caused by deficient function of the alpha-galactosidase A (a-GalA)
enzyme. a-GalA deficiency leads to multisystemic clinical manifestations caused by the preferential accumulation of globo-
triaosylceramide (Gb3) in the endothelium and vascular smooth muscles. A hallmark symptom of Fabry disease patients is
neuropathic pain that appears in the early stage of the disease as a result of peripheral small fiber damage. The a-GalA gene
null mouse model (a-GalA(/0)) has provided molecular evidence for the molecular alterations in small type-C nociceptors
in Fabry disease that may underlie their hyperexcitability, although the specific mechanism remains elusive. Here, we have
addressed this question and report that small type-C nociceptors from a-GalA(/0) mice exhibit a significant increase in the
expression and function of the TRPV1 channel, a thermoTRP channel implicated in painful heat sensation. Notably, male a-
GalA(/0) mice displayed a &2-fold higher heat sensitivity than wild-type animals, consistent with the augmented expression
levels and activity of TRPV1 in a-GalA(/0) nociceptors. Intriguingly, blockade of neuronal exocytosis with peptide
DD04107, a process that inhibits among others the algesic membrane recruitment of TRPV1 channels in peptidergic noci-
ceptors, virtually eliminated the enhanced heat nociception of a-GalA(/0) mice. Together, these findings suggest that the
augmented expression of TRPV1 in a-GalA(/0) nociceptors may underly at least in part their increased heat sensitivity, and
imply that blockade of peripheral neuronal exocytosis may be a valuable pharmacological strategy to reduce pain in Fabry
disease patients, increasing their quality of life.
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Introduction
Fabry disease (FD) is a X-linked lysosomal storage dis-
order caused by the deficient activity of a-galactosidase
A (a-Gal A), encoded by the GLA gene (Xq22.1), which
is responsible for the catabolism of neutral glycosphin-
golipids.1 Deficient enzymatic activity results in the pro-
gressive intralysosomal deposition of glycosphingolipids,
predominantly globotriaosylceramide (Gb3), in a variety
of cell types, including capillary endothelial cells, renal
(podocytes, tubular cells, glomerular endothelial, mesan-
gial and intersticial cells), cardiac (cardiomyocytes and
fibroblasts), smooth-muscle cells, and nerve cells.2
Therefore, the consequence is the accumulation of the
sphingolipid globotriaosylceramide (Gb3) in multiple
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organs, particularly in kidneys, heart, and the nervous
system.3 The early manifestations of FD appear in
childhood and usually include acroparesthesia, angioker-
atomas, hypohidrosis and pain. Episodes of acute, ago-
nizing pain, typically beginning in the extremities and
radiating inward, may persist from minutes to several
days, giving rise to the Fabry pain crisis.4 The first
signs appear already in childhood and with age, severe
complications cause considerable morbidity and prema-
ture death involving the kidneys, heart, and brain.5,6 It
remains difficult to clearly define such a phenomenon as
the pain. In medical conditions, pain is a symptom, a
response to noxious stimuli, such as cold or heat,
detected by peripheral damage-sensing neurons (nocicep-
tors, peripheral terminals), mechanical stress or the
chemical signals arising during inflammation. It is car-
ried through small diameter nerve fibers to the central
nervous system (CNS). Specifically, it has been demon-
strated that FD patients show reduced intraepidermal
nerve fiber density and altered thermal perception.7
The underlying molecular and functional mechanisms
of pain in small fiber neuropathy patients with FD are
still not completely understood, although a small fiber
peripheral neuropathy affecting small unmyelinated and
myelinated nerve fibers is frequently found.8,9 Pain in FD
is assumed to be neuropathic because Gb3 deposits have
been observed in dorsal root ganglia of Fabry
patients.10–12 Our first hypothesis, at the molecular
level, was referred to the role of the Gb3 deposits in the
cell bodies of cells as a typical feature of FD patients.13,14
Specifically, Gb3 accumulations would interfere with the
function of cellular membrane proteins and receptors
leading to a direct pathological effect on ganglia or
axons of small peripheral sensory neurons in pain percep-
tion and/or transduction.14–16 In a previous study, we
reported that a-GalA null mice displayed neuropathic
pain evidenced by thermal hyperalgesia, mechanical allo-
dynia, and histological analyses.12 These findings sug-
gested that this was a good model to study the
peripheral small fiber neuropathy exhibited by FD and
provide molecular evidence for the hyperexcitability of
small nociceptors in FD. Notably, at the molecular
level, the a-GalA(/0) animals showed significant
increase immunoreactivity of TRPV1 and Nav1.8, and
a decrease immunoreactivity of TRPM8 ion channels in
their cutaneous terminals.13 Thereafter, it has been sug-
gested that the accumulation of elevated glycosphingoli-
pids concentration in sensory neurons have a direct role
in their enhanced excitability.17–19 Moreover, a modula-
tory effect of lyso-Gb3 on voltage-gated calcium currents
has also been suggested in the same mouse model.20
In the present study, we report that the a-Gal(/0)
male mice DRG exhibit molecular and structural alter-
ations in painful heat sensation consistent with overex-
pression and enhanced activity of TRPV1 ion channel.
Blockade of TRPV1 neuronal exocytosis with peptide
DD04107 results in attenuation of heat hypersensitivity.
These findings provide a key suggestion to possible
mechanism underlying the higher heat sensitivity of FD




Heterozygous female mice for a-GalA gene deletion (a-
GalA(þ/)), JAX strain B6;129-Glatm1Kul/J (stock
number 003535), and wild-type (WT) male a-GalA(þ/
þ) were purchased from Charles River Laboratories
Italia SRL (Jackson Laboratory; Bar Harbor, ME). To
obtain a-GalA(/0) hemizygous male mice, we crossed
the a-GalA(þ/) female and a-GalA(/0) male mice.
The mice were housed in groups of six in individually
ventilated cages (Tecniplast, Italia) with water and food
ad libitum in controlled environmental conditions: lights
on from 7.00 a.m. to 7.00 p.m., 22 2C temperature
and 65% humidity. For the results of this work, we
used only males for both, a-GalA(/0) and a-GalA(þ/
þ) mice; because of the greater severity demonstrated in
males, we decided to focus our study only on the animal
model of WT and knockout (KO) males. Behavioral
experiments were carried out at the Department of
Medical and Clinical Sciences of the University of
Bologna with the approval of the local ethical committee
(Veterinary Service of the University of Bologna) and in
agreement with the National Animal Welfare Act. All
efforts were made to minimize animal suffering and the
number of animals used was kept to a minimum by the
experimental design. All the procedures followed in this
work complied with the European Community Council
Directive of 24 November 1986 (86/609/EEC) and were
approved by the Ethical committee of the University of
Bologna (prot. N.43.IX/9). The age of animals used for
behavioral and immunohistochemistry experiments was
in the range of 8 to 12 weeks.
Genotyping
Genomic DNA was extracted from tail biopsies and
genotyping of a-GalA KO mice was as described
before13 using polymerase chain reactions with three
oligonucleotides: oIMR5947 5’-AGGTCCACAGC
AAAGGATTG-3’, oIMR5948 5’-GCAAGTTGCCC
TCTGACTTC-3’, and oIMR7415 5’-GCCAGAGG
CCACTTGTGTAG-3’. The primers amplified bands of
202 bp for a-GalA(/) and 295 bp for a-GalA(þ/þ).
The polymerase chain reaction conditions: 94C for
3min, 35 cycles of 94C for 30 s, 64C for 1min and
72C for 1min, final elongation at 72C for 2min.
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Preparation of rat dorsal root ganglion neuron
Primary cultures of DRG neurons were prepared from
adult 8 to 12 weeks males, according to previously
described protocols with some modifications.21 The
mice were anesthetized by Halothane prior to decapita-
tion. All ganglia were removed from each mouse and
transferred in ice-cold Dulbecco’s Phosphate Buffered
Saline (DPBS) 1 (Gibco) and next the roots were cut
using micro dissecting scissors. After rinsing in
Dulbecco’s Modified Eagle Medium (DMEM) (Gibco),
the ganglia were placed in DMEM containing 5000 U/
mL type IV collagenase (Worthington) for 45–75min at
37C, 5% CO2, washed twice by medium with Fetal
bovine serum (FBS) and then gently dissociated mech-
anically with passages through 0.5mm and 0.6mm sterile
needles. Cells were centrifuge for 10min at low speed and
then appropriately diluted in 1mL of DMEM medium
containing 10% FBS (Gibco), 50 ng/mL nerve growth
factor (Gibco), and 1.5mg/mL cytosine b-D-arabinofur-
anoside (AraC, Sigma). For electrophysiology experi-
ments, single cell suspension was plated at
concentration 5,000 cells/2mL of growing medium on
polylysine (Sigma) with Laminin (Gibco) precoated cul-
ture dishes. For whole protein extraction 60,000 cells/
5mL were plated onto polylysine precoated culture
dishes. For immunocytochemistry, 15,000 cell/mL were
plated onto 18mm round glass coverslips, precoated
with polylysine and laminin. Cell culture was maintained
in a 37C, 5% CO2 incubator during different periods
(for electrophysiology experiments, the cells were used
within first four days after plating (Days in vitro
[DIV]); for Western Blot (WB), analysis and immuno-
cytochemistry was used the same period and in parallel
the 6 DIV). Cells were maintained in DMEM, supple-
mented with 10% FBS in the presence of 50 ng/mL nerve
growth factor and 1.5mg/mL cytosine b-D-arabinofura-
noside (AraC, Sigma) to reduce glial cell expression. Half
volume of medium was changed every second day.
Immunohistochemistry
For the immunohistochemistry of skin biopsy, the males
of each genotype were deeply anesthetized with
Isoflurane, shaved on the back, and rectangular section
of 5mm 5mm from the middle of the back (on top of
the spine) was trimmed using a scalpel. In this manner,
we reached a good view of the interfollicular epidermis as
well as the hair follicles in the sagittal sections. We
placed the piece of skin on Whatman filter paper
(dermis side down) and fixed it in 4% paraformaldehyde
(Sigma) rinsed in phosphate-buffered saline (PBS)
(0.01M, pH 7.4) at 4C for three days. After fixation,
we replaced the fixative solution with cryoprotective
solution of 30% sucrose (Sigma). The skin biopsies
were mounted in Tissue Tek OCT compound, frozen
and cryosectioned at 50 mm parallel to spine axis orien-
tation (longitudinal free-floating sections). The immuno-
histochemistry of floating sections was processed in
separated chambers for each genotype, reaching the
same conditions for all three animals. The number of
immunohistochemistry experiments was three and the
total number of used animals was three for WT and
three for KO. Sections were blocked with 5% bovine
serum albumin (BSA) (Sigma) rinsed in PBS (0.01M,
pH 7.4) with 0.5% of triton X-100 (Sigma) for 1 h at
room temperature, followed by incubation overnight
with primary antibody rabbit anti-pan-neuronal marker
PGP9.5 (1:1000; Serotec, Raleigh, NC) in 1%
BSA rinsed in PBS (0.01M, pH 7.4) with 0.5% of
Triton X-100 at 4C. After washing, they were incubated
with secondary antibody Cy3-donkey anti-rabbit (1:200,
Jackson ImmunoResearch) in 1% BSA rinsed in PBS
(0.01M, pH 7.4) with 0.05% of Triton X-100 for 2 h at
room temperature. Finally, the sections were mounted
into Fluoromount-G mounting medium containing
DAPI (40,6-diaminobenzidine-2-phenylindole, dilactate,
Sigma). Experimental, negative control samples were
processed in parallel in different reaction chambers, with-
out incubation with primary antibody. The fluorescent
signal of negative control sample was taken as a thresh-
old for fluorescent signal of experimental samples.
Cryosections of whole DRGs
Samples of whole DRG were isolated from 8 - to
10-week-old animals and immediately fixed in 4% par-
aformaldehyde (Sigma) rinsed in PBS (0.01M, pH 7.4) at
4C for three days. After the fixation, we replaced the
fixative solution with cryoprotective solution of 30%
sucrose (Sigma). The spinal cord and DRG were cut
into 10 and 20 mm sections, respectively. The 20 mm sec-
tions were incubated with hematoxylin and eosin stain-
ing solutions, and the 10 mm were incubated with rabbit
anti-TRPV1 (1:50, Santa Cruz) and mouse anti-NeuN
(1:2000, Millipore) overnight at 4C in 1% BSA with
0.05% of Triton, then incubated with Cy2-donkey anti-
mouse and Cy3-donkey anti-rabbit (1:200, from Jackson
ImmunoResearch) for 2 h at Troom in dark. DAPI (dilac-
tate; 300 nM, Invitrogen) was used for counterstaining.
Images were taken by a confocal microscope.
Immunocytochemistry
DRG neurons of different time of growth (from 3 to 12
DIV) were fixed for 20min with 4% paraformaldehyde
(Sigma) rinsed in PBS (0.01M, pH 7.4) at room tempera-
ture, followed by washes with PBS, blocking in 5% BSA
(Sigma) with 0.5% of triton (Sigma), and incubation with
primary antibodies overnight at 4C in 1% BSA with
0.05% of Triton. Following day, the primary antibodies
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were washed out by 1PBS and followed by incubation
with Cy2, Cy3-conjungated secondary antibodies
(Jackson ImmunoResearch) for 2 h at Troom in dark.
Primary antibodies: goat anti-Nav1.8 (1:50, Santa
Cruz),22 rabbit anti-TRPV1 (1:50, Santa Cruz),23–25
rabbit anti-TRPM8 (1:50, Santa Cruz), rat anti-CD77
(1:10, Abcam),26 mouse anti-NeuN (1:2000, Millipore),27
and rabbit anti-Tuj1 (b3 Tubulin, 1:50, Santa Cruz).28
Secondary antibodies: Cy2-donkey anti-rabbit, Cy2-
donkey anti-mouse, Cy3-donkey anti-rat, and Cy3-
donkey anti-rabbit (1:200, all from Jackson
ImmunoResearch). DAPI (dilactate; 300nM, Invitrogen)
was used for counterstaining.
Western blot
Protein extracts were prepared from DRG neurons of
different time of growth (from 3 to 6 DIV) homogenized
with of lysis buffer (50mM TRIS-HCl, pH 7.4, 100mM
NaCl, 1mM PMSF, 1mM EDTA, 5mM Iodacetamide,
1% Triton X-100, 0.5% Sodium Dodecysulfate). The
extracts were sonicated for 10min in 20 s intervals
every 2min and pelleted for 30min at 12,000 r/min.
The supernatant was collected and used to determine
the protein content using the Bradford method.
Tissue lysates (40–80 g) were separated by 7.5%–10%
SDS-polyacrylamide gel and transferred to hybond-ECL
nitrocellulose membrane (Amersham). After transfer, the
membrane was blocked by 5% BSA in PBS (0.01M, pH
7.4) with 0.05% Tween 20 (Sigma) (PBST) for 1 h at
room temperature. The membrane was incubated with
primary antibodies against specific ionic channels goat
anti-Nav1.8 (1:200, Santa Cruz), rabbit anti-TRPV1
(1:250, Immunological Sciences), rabbit anti-TRPM8
(1:100; Santa Cruz), and rabbit anti-actin (1:200,
Sigma) in 1% BSA in PBST overnight at 4C. The mem-
brane was rinsed three times with PBST, each for 15min
and secondary antibody horseradish peroxidase-coupled
secondary anti-rabbit (1:2000, Santa Cruz) and anti-goat
(1:5000, Sigma) were employed for incubation in 1%
BSA rinsed in PBST for 2 h at Troom. After washout of
secondary-HRP binding antibody, the membrane was
incubated with chemiluminiscence substrate (Santa
Cruz) for 5min; protein bands were visualized on X-
ray (Thermo Scientific). The intensity of the protein
bands for all observed ICs (TRPV1, Nav1.8, and
TRPM8) was quantified and normalized to the intensity
of b-actin bands using the ImageJ software.
Evaluation of epidermal nerve fiber density in mice
skin biopsy
The epidermal nerve fiber density identified by PGP 9.5
positive staining was calculated per linear millimeter of
epidermis.29 The images of PGP9.5 positive immunos-
taining of mice skin biopsy acquired with 40 objective
were analyzed using the ImageJ software. Only the neur-
onal fibers within the epidermis were taken into account.
The total number of counted neuronal fibers was related
to the final length of dermal/epidermal border.
Evaluation of TRPV1 expressing neuronal population
in whole DRG sections
The total number of NeuN and/or TRPV1 positive
cells was counted in 27 randomly chosen images, taken
as Z-stack on Nikon confocal microscope. The ratio of
TRPV1 expressing neurons per whole neuronal popula-
tion (total number of neurons) for each genotype was
calculated and represented as a percentage.
Electrophysiology
Salts and other chemicals were of the highest purity
grade (Sigma-Aldrich). Cells were visualized with a
phase-contrast inverted microscope (Nikon Italy,
Firenze, Italy).
Voltage-clamp experiments were performed at room
temperature (20C–22C) with the whole-cell configur-
ation of the patch clamp technique.30 DRG neurons
were bathed in extracellular solution containing (in
mM): 140 NaCl, 4 KCl, 2 CaCl2, 2 MgCl2, 10
HEPES, 5 Glucose, pH 7.4 with NaOH (320 mOsm/
Kg with mannitol). To measure cationic currents,
DRG were perfused with extracellular solution contain-
ing (in mM): 140 NaCl, 4 CsCl, 1 MgCl2, 2 CaCl2, 10
HEPES, 10 Glucose, pH 7.4 with CsOH (320 mOsm/
Kg). The pipette solution contained (in mM): 140
CsCl, 1 MgCl2, 5 EGTA, 10 HEPES, 10mM Glucose,
3mM ATP, pH 7.2 with CsOH (290 mOsm). The osmo-
lality of all solutions was measured with a vapor–pres-
sure osmometer (Wescor 5500, Delcon Italy). Patch
pipettes were prepared from thin-walled borosilicate
glass capillaries to have a tip resistance of 2–10MV
when filled with the pipette solution. Membrane currents
were amplified by an EPC-7 amplifier (List Electronic
Darmstadt, Germany), filtered at 2Hz (3 dB) and
acquired at a sample rate of 5 kHz on a microcomputer
for off-line analysis (pClamp 6, Axon Instruments,
Foster City, CA, USA). Cell capacitance of the recorded
cell was estimated by on-line electronic correction of cap-
acitive transients. Values of current density were calcu-
lated by dividing the whole-cell currents by the cell
capacitance. Capsaicin and capsazepine were dissolved
in DMSO at a concentration of 10mM and diluted to
the working concentration of 1 mM for capsaicin and
10 mM for capsazepine in external solution the same
day of the experiment.
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Hot plate test
Mice of age 8–12 weeks (&30 g) were used for the study.
The animals were positioned in the experimental room
1h before the test. DD04107 (kindly provided by BCN
Peptides) was diluted in 0.9% saline and was adminis-
tered subcutaneously at the doses of 3mg/kg (nWT¼ 14;
nKO¼ 14). For the control groups of experiments, 100 ml
of 0.9% saline was administered subcutaneously
(nWT¼ 15; nKO¼ 15).
Each mouse was placed into a transparent beaker
made of Plexiglas of 60 cm and a diameter of 18 cm to
avoid the animals escaping from the plate which
temperature was set at 52C 0.1C by using a
thermo-regulated heated plate (Ugo Basile, Varese,
Italy). The time (in seconds) between the placement of
the animal and the first response: paw licking/fanning or
jumping was measured as latency. A 30-s cut-off was
used to prevent tissue damage. The measurements
started 2 h after the administration of saline/DD04107
and were repeated in intervals of 4, 8, 24, 48, 56,
and 168 h.
Data acquisition
Fluorescent images were captured with a Nikon D-
Eclipse C1 inverted laser scanning confocal microscope.
Images were collected as single focal sections separately
for each channel. EZ-C1 3.90 Free Viewer, Image J
(NIH), and Adobe Photoshop software were used for
image capture and analysis.
Statistical analysis
ImageJ (gel analyser plugin) was used for quantification
of Western blots; and GraphPad Prism 5 (GraphPad
Prism Software) was used to perform an Fisher’s exact
test for statistical significance for differences in protein
expression and unpaired paired Student’s t-test one-
tailed for electrophysiological results and whole DRGs
section evaluation. Two-way repeated-measure ANOVA
followed by least significant difference Fisher’s post hoc
test was performed to analyze behavioral data. Values
shown represent meanSEM. A P-value of <0.05 (*),
p< 0.01 (**), and p< 0.001 (***).
Results
Altered innervation of -GalA(/0) mice dorsal skin
Mutant genes were determined as previously described
by Lakoma et al.13 We recently reported that the expres-
sion of the neuronal marker PGP9.5 showed a significant
decreased and scattered pattern of neuronal terminations
in the frontal skin paw of a-GalA(/0) males in
comparison to their WT littermates. This parallels the
observation of a decrease in neuronal terminations
marked by PGP9.5 in skin biopsies of human patients
with small fiber neuropathies.14,31 Thus, we next
examined the epidermis of dorsal skin of a-GalA(/0)
individuals compared with WT mice. Since we observed,
the disease severity affects more strongly males than
females, we focused our study only on males. The immu-
nohistochemistry of floating sagittal sections of mice
back skin biopsies revealed a significant decrease in
dermal PGP9.5 positive neuronal terminations in a-
GalA(/0) mice (Figure 1(a) white arrows). Notably,
Figure 1. Innervation of a-GalA KOMouse skin biopsy. (a) The
immunostaining of 50 mm floating sagittal sections of mice back skin
biopsy revealed a decrease in PGP9.5 positive innervation (white)
in a-GalA KO males (n¼ 3) in comparison to their WT controls
(n¼ 3). Scale bar represents 100 mm. (b) Quantitative analysis of
neuronal fibers terminations in epidermis of mice back skin biopsy
showed significant decrease (about 30%; p¼ 0.0179) in a-GalA KO
males in comparison to WT.
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density of the epidermal nerve fibers was significantly
decreased in a-GalA(/0) mice compared with WT
(30% less PGP 9.5 positive fibers in a-GalA(/0) (2.44
fibers/mm) in comparison to WT (3.26 fibers/mm);
Figure 1, p¼ 0.02, n¼ 3 animals for WT and GalA(/
0)). These results substantiate our previous observation
in a-GalA(/0) mice frontal paws13 and indicates a gen-
eral phenotype for peripheral nervous system (PNS) in
FD in the animal model that matches that of humans.
Morphological structure and characterization of WT
versus KO DRG neurons
To examine the morphology and level of Gb3 expression
in WT and a-GalA(/0) DRG neurons, III beta-tubulin
(Tuj-1), Gb3, and NeuN expression were monitored by
immunocytochemistry (Figure 2). NeuN was used as a
neuron-specific nuclear protein determining the neuronal
specificity of neurons in the primary culture isolated
from DRGs. The cytoplasm marker of most neuronal
cell types Tuj-1 was employed to visualize the neurites
length and morphology of neuronal cell
body.Interestingly, we observed a high level of expres-
sion of Gb3 in a-GalA(/0) DRGs in comparison to WT
(Figure 2(b) from middle panel). This increased
expression corroborates the accumulation of Gb3 in
sensory terminals as a hallmark of FD. In addition,
a-GalA(/0) DRG terminals show a significant volume
increase compared with WT as evidenced by Tuj-1 label-
ing of DRG neuronal bodies (Figure 2(c),(f) p¼ 0.0168,
n¼ 3 animals).
Increase of TRPV1 protein expression in
Fabry mice DRG neurons
We have recently proposed that the higher pain percep-
tion in Fabry patients and the in a-Gal A(/0) mice is
primarily due to an altered peripheral expression of ion
channels involved in sensory pain transduction such as
TRPV1, TRPM8, and Nav1.8, as that detected in per-
ipheral terminals.13 Next, we sought to substantiate this
tenet in in vitro-cultured DRG neurons isolated from a-
GalA(/0) and WT mice. We evaluated the expression of
TRPV1, TRPM8, and Nav1.8 in primary cultures of
DRG neurons from a-GalA(/0) and WT male mice.
As illustrated by Figure 3(a) to (d), we observed a
higher fluorescent signal of TRPV1 in a-GalA(/0)
than in WT nociceptors. This finding was further
Figure 2. Characterization of DRG neurons in culture from WT (a-b-c)and KO mice (d-e-f). Immunocytochemistry of NeuN positive
(green) DRG neurons clearly shows accumulation of globotriaosylceramide (Gb3) (red) in the cells of KO in comparison to WT mice. III
beta-tubulin (anti-Tuj1) staining of DRGs (green, right panel) showed significant increase (p¼ 0.0168) in the KO DRG neurons (n¼ 73) in
comparison to WT (n¼ 72). Scale bars represent 50 and 25mm.
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confirmed by quantitative Western Blot analysis. In fact,
protein expression analysis revealed a 1.25-fold increase
of TRPV1 protein expression in the total DRG protein
extraction from a-GalA(/0) mice compared with WT
(Figure 3(e), (f) p¼ 0.03, n¼ 5 animals). In contrast,
TRPM8 levels were not altered in the a-GalA(/0)
nociceptors (Figure 4, p¼ 0.3, n¼ 5). A similar result
was obtained for the levels of Nav1.8 (Figure 5,
p¼ 0.4, n¼ 5). These results corroborate that the thermal
hyperalgesia previously detected in in vivo Fabry murine
model13 is mainly due to an increased protein expression
of TRPV1 in DRG nociceptors.
Figure 3. TRPV1 detection in seven days cultured DRG neurons. (a–c) Immunocytochemistry of DRGs from a-GalA KO males (n¼ 5)
showed different expression at the protein level of the specific TRPV1 receptor (red) in comparison to their WT controls (n¼ 5). The
neuronal nuclear lineage-specific marker NeuN is shown in green. (b–d) High magnification of DRG neurons double stained for TRPV1
(red) and NeuN (green). (e) The Western blot analysis of TRPV1 expression  92/110–113 kDa. (f) The quantitative analysis of three
independent experiments of TRPV1 expression immune-blots in the whole protein extract from DRGs cultures pooled from five males for
each genotype showed the 25% increase in protein expression of TRPV1 in case of a-GalA KO males when compared with WT (p¼ 0.030).
The scale bars represent 50 and 25 mm.
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TRPV1 receptor immunostaining in -GalA(/0)
DRG sections
We next performed immunohistochemical staining on
mice DRG cryosections from a-GalA(/0) mice, in
order to check receptor distribution in sensory fibers
and prove whether TRPV1 was overexpressed not only
in the in vitro condition. In Figure 6, representative
hematoxylin/eosin staining for anatomical demonstra-
tion of DRGs and immunofluorescence images are
Figure 4. TRPM8 detection in seven days cultured DRG neurons. (a–c) Immunocytochemistry of DRGs from a-GalA KO males (n¼ 5)
showed similar expression at the protein level of the specific TRPM8 receptor (red) in comparison to their WT controls (n¼ 5). The
neuronal nuclear lineage-specific marker NeuN is shown in green. (b–d) High magnification of DRG neurons double stained for TRPM8
(red) and NeuN (green). (e) The Western blot analysis of TRPM8 expression (  127 kDa) revealed no differences in the protein
expression in case of a-GalA KO males (n¼ 5) when compared with WT (n¼ 5). (f) The quantitative analysis of two independent
experiments of TRPM8 expression immuno-blots in the whole protein extract from DRGs cultures pooled from 2–3 males for each
genotype clearly showed no differences in protein expression of TRPM8 in case of a-GalA KO males when compared with WT. The scale
bars represent 50 and 25 mm.
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reported. The morphological structure of the a-GalA(/
0) mice model DRGs and their WT littermates, stained
with hematoxylin and eosin staining, showed a fully
developed DRG neurons system without histological
alterations in both genotypes (Figure 6(a) and (d).
Conversely, the Gb3 positive staining was observed
exclusively in the sections of a-GalA(/0) DRG
(Figure 6(b) and (e)). In parallel, the a-GalA(/0) mice
neurons exhibits a more pronounced positive staining for
TRPV1 compared with controls (Figure 6(c) and (f)).
Figure 5. Nav1.8 detection in seven days cultured DRG neurons. (a–c) Immunocytochemistry of DRG neurons from a-GalA KO males
(n¼ 5) showed slightly different expression at the protein level of the specific Nav1.8 receptor (red) in comparison to their WT controls
(n¼ 5). The neuronal nuclear lineage-specific marker NeuN shown in green. (b–d) High magnification of DRG neurons double stained for
Nav1.8 (red) and NeuN (green). (e) The Western blot analysis of Nav1.8 expression (  220 kDa) revealed no difference in protein
expression in case of a-GalA KO males (n¼ 5) when compared with WT (n¼ 5). (f) The quantitative analysis of two independent
experiments of Nav1.8 expression immune-blots in the whole protein extract from DRGs cultures pooled from three males for each
genotype clearly showed no differences in protein expression of Nav1.8 in case of a-GalA KO males when compared with WT. The scale
bars represent 50 and 25mm.
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Taking together, these results indicate that TRPV1 is
again overexpressed in the cryosections of whole trigem-
inal ganglia isolated DRG neurons from a-GalA(/0)
mice compared with control littermates (Figure 6(g)).
Functional expression of TRPV1 receptor in -
GalA(/0) DRG neurons
A question that emerges is whether the augmented pro-
tein expression of TRPV1 in nociceptors was paralleled
by an increased activity as higher protein expression does
not necessarily results in augmented TRPV1 responses
due to potential channel clustering.32,33 Thus, we next
evaluated capsaicin-activated currents by patch-clamp
in whole cell configuration. It should be noted that we
frequently observed in DRG neurons of a-GalA(/0)
mice that the cell membrane was extremely sticky and
easily perforated by the patch-electrode giving rise to
low-resistance seals. This particular characteristic was
even more noticeable in the plasma membrane of neu-
rons isolated from older animals (the time window of
animals used for DRG isolation was from 8 to 12
Figure 6. TRPV1 and Gb3 expression in whole DRG. Cryostat sections (20 m) of DRG from a-GalA(/0)and WT, were stained with
hematoxylin/eosin (a, d) and (10 m) immunostained with antibodies for Gb3, TRPV1, and NeuN (b–f). The quantitative analysis of two
independent TRPV1/NeuN immunostainings in whole DRG revealed significant increase (p¼ 0.0306) in TRPV1 expressing neuronal
population of a-GalA(/0) mice in comparison to their WT controls G). n¼ 27 for both WT and KO represents the number of randomly
chosen images for final evaluation; for each genotype were used three males of eight weeks of age. Representative immunofluorescence
images are reported. The scale bars represent 100 mm.
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weeks). Most likely, due to this fact, we patched a lower
number of nociceptors of a-GalA(/0) than from WT
mice. Figure 7(a) depicts that small diameter DRG neu-
rons responded to 1 mM capsaicin application by activat-
ing an inward cationic current of 5150 pA in WT DRG
nociceptors and 5300 pA in KO DRG neurons
(Figure 7(a), (c)). This current was fully blocked by
10 mM capsazepine. A quantitative assessment of the
TRPV1 activity measuring the capsaicin current density
shows that a-GalA(/0) nociceptors had a mean
17.15 pA/pF at a holding potential of 60mV
(Figure 7(d)), while WT nociceptors exhibited
10.84 pA/pF, demonstrating a statistical enhancement
of the TRPV1 current in the dissociated nociceptive
DRG neurons in vitro. Intriguingly, the percentage of
nociceptors responding to capsaicin was significantly
lower in a-Gal A(/0) nociceptor primary cultures
(Figure S1(a), 35% of a-GalA(/0) and 60% for WT
DRG neurons responded to capsaicin). It is worth to
mention that during the experimental window of 72 h
after cellular plating, we observed the decrease in the
TRPV1 capsaicin-evoked currents with the time of cul-
ture. This can lead the hypothetic decrease in sensibility
to capsaicin-activated currents in older DRG neurons
(Figure S1C, D).
Thermal sensitivity of -GalA(/0) is attenuated by
blocking regulated exocytosis
The finding that TRPV1 is highly expressed in nocicep-
tors from a-GalA(/0) mice suggest that these mice may
exhibit higher thermal sensitivity than WT animals. To
evaluate the thermal nociception of the transgenic and
WT mice, we measured the latency to the first response in
the hot-plate test at 52C 0.1C. As depicted in
Figure 8(a), a-GalA(/0) mice exhibited a &2-fold
lower latency to the noxious heat stimulus than WT
mice, indicating an augmented thermal sensitivity of
Figure 7. Capsaicin evoked ionic currents from DRG neurons in culture. (a) Representative currents activated by 1mM capsaicin and
blocked by 10mM capsazepine in a-GalA(/0) and control mice. Sensory neurons were held at 60 mV. The amplitude of capsaicin-evoked
inward current was greatly increased in a small-diameter dorsal root ganglion (DRG) neuron of a-GalA(/0) compared with capsaicin-
induced inward cationic current in a control small DRG sensory neuron. Compared with capsaicin-induced inward cationic current in a
control small DRG sensory neuron, the amplitude of capsaicin-evoked inward current was greatly increased in a small-diameter DRG
neuron from a-GalA(/0) (b) Percentage of capsaicin responding cells—the percentage of small diameter DRG neurons responding to
1 mM capsaicin stimuli was lower in a-GalA(/0) (35%) in comparison to its WT control (60%). (c) Quantitative representation of TRPV1
currents recorded at 60 mV. Values are given as means SE; n¼ 8 for WT and n¼ 5 for KO cells. *p< 0.0184. (d) Quantitative
assessment of TRPV1 currents density by normalization of peak current recorded at 60 mV to the capacitance of each cell. Values are
given as means SE; n¼ 8 for WT and n¼ 5 for KO cells. *p< 0.05.
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the transgenic mice. This enhanced thermal sensitivity
may be due to an increased TRPV1 activity and/or to
an enhanced surface expression of the receptor.34–36
Indeed, it has been reported that TRPV1 sensitization
in nociceptors is in part due to the algesic-induced
exocytotic recruitment of this receptor to the neuronal
surface of peptidergic nociceptors.21,37 Blockade of
Ca2þ-dependent exocytosis in nociceptors using com-
pound DD04107 prevents the algesic-induced exocytotic
recruitment of TRPV121,37 and produces thermal anti-
nociception in models of chronic pain.37,38 Thus, we
hypothesized that blockade of neuronal exocytosis
may modulate the surface expression of TRPV1 in a-
GalA(/0) nociceptors and attenuate the thermal hyper-
sensitivity of the transgenic mice. To address this
hypothesis, we evaluated the effect on the thermal
nociception of peptide DD04107 (3mg/kg, s.c.) in a-
GalA(/0) mice (Figure 8(b)). As illustrated, injection
of the peptide resulted in a significant reduction of the
thermal sensitivity as revealed by the increase of the
latency to the heat response up to the level of WT ani-
mals. Furthermore, the peptide effect lasted up to 24 h
post injection (Figure S2). As reported previously,38 pep-
tide DD04107 did not have a significant effect on the
thermal nociception of WT animals (data not shown).
These results imply that the augmented thermal nocicep-
tion of a-GalA(/0) mice may be attenuated by blocking
regulated exocytosis in nociceptors and suggest that the
enhanced expression of TRPV1 in a-GalA(/0) nocicep-
tors may produce an increment in the membrane recruit-
ment of the channel leading to heat hypersensitivity.
Discussion
FD is a rare multisystemic inherited metabolic disease
with profound effects on almost all organs.39 FD has a
childhood onset and frequently leads to early mortality
of untreated patients.40 Neuropathic pain and somato-
sensory disturbances are often the first representative
symptoms in FD and can be episodic, with agonizing
burning pain in the hands and feet, or chronic, with
burning or shooting pain, or dysesthesias.41 The patho-
physiology of the altered sensory neurons function in FD
remains poorly understood. The manifestations at the
neurological level occur in both the PNS and CNS.
The important consequences of Gb3 accumulation
were assigned to a potential mechanism of cerebral ische-
mia in FD patients which results from Gb3 storage in the
vascular epithelium. Gb3 accumulation in neurons of
CNS is predominantly involved in the cerebrovascular
events42 characterized by cerebral vasculopathy, various
anatomical abnormalities (e.g., small and large vessels),
impairment of endothelial function,43,44 and cerebral
blood flow dysregulation;45 in early age at onset and
abnormal brain magnetic resonance imagings. Early
treatment of FD patients with enzyme replacement ther-
apy (ERT) is the key therapeutic goal to avoid multiple
organ damage.10 Interestingly, the evidence of the ERT
beneficial effects is reported in the improvement of Gb3
reduction in organ and tissues.46 Nevertheless, minimum
of six months treatment is required to reveal the positive
effect of ERT on neuropathic pain.47,48
Recently, the characterization of a FD mouse
model49,50 opened the possibility to interrogate the func-
tional and structural involvement of PNS components in
the mechanism contributing to pain in FD patients.
Rodrigues et al.51 published a detailed histological ana-
lysis of cytoarchitecture of Fabry mice sciatic nerves.
There was also observed the lipid accumulation in
DRG of Fabry patients, even its effect on sensory neu-
rons was not studied.12,52 Furthermore, the group of
Choi et al.16,20,53 has concentrated their scientific interest
Figure 8. Decrease in thermal sensitivity. (a) The statistically significant reduction in latency time of male KO group 2 h after the
administration of saline demonstrates higher acute sensitivity to noxious hot thermal stimulation than in WT male group (p¼ 0.01, n¼ 14
animals for WT, n¼ 14 animals for KO). (b) The same interval of 2 h after the subcutaneous administration of 3 mg/kg DD04107 peptide
showed significantly reduced thermal sensitivity generated in the a-GalA(/0) mouse model of FD (n¼ 15) by hot-plate stimulus of
52C 0.1C when compared with a-GalA(/0) KO mice injected with saline (n¼ 14) (p¼ 0.02). Two-way ANOVA for Treatment effect
F(1, 54)¼ 1.32, p¼ 0.25, Genotype effect: F(1, 54)¼ 4.01, p¼ 0.05; Genotype effect x Treatment effect F(1, 54)¼ 5.02, p¼ 0.02).
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into the effect on FD-associated lipid Lyso-Gb3 (deace-
tylated form of Gb3) in DRG neurons of adult mice and
cellular fibroblast line. The nature and temporal effects
of the Gb3 substrate accumulation on tissue histology in
Fabry mice was recently characterized by Bangari et al.54
It is important to highlight that Shen and coworkers
recently published a detailed study employing a new
derivate of alpha-Gal (Moss alpha-Gal; which is identi-
cal to the native human alpha-Gal) in mice FD model,
proposing this enzyme as a future possible agent for
ERT of Fabry patients.55 In this context, it would be
an interesting idea to unveil the ERT effect on neuro-
pathic pain in FD mouse model.
The plasma circulation of Lyso-Gb3 and the concomi-
tant lysosomal accumulation of Gb3 in sensory neurons
has been proposed to lead to pain in FD.56 Moreover, it
has been demonstrated that the intraplantar injection of
Lyso-Gb3 in healthy mice developed mechanical allody-
nia through sensitizing of DRG neurons. In parallel, the
effect of Lyso-Gb3 incubation on mice sensory neurons
led to a significant enhancement of voltage-gated calcium
currents and intracellular Ca2þ in capsaicin positive sen-
sory neurons.16 In the present study, we hypothesized
that during chronic inflammatory or neuropathic pain,
upregulated TRPV1 channels induce hyperactivity of
DRG nociceptive neurons and thermal sensitivity by dir-
ectly enhancing the channel function. According to our
previous findings, the a-GalA(/0) male mouse is an
appropriate disease model to study the peripheral small
fiber neuropathy exhibited by FD patients and to pro-
vide molecular evidence for the hyperexcitability of small
nociceptors in FD.13,14 In parallel, the dysfunctions of
ion channels widely distributed in human Ad and C-
fibers has been proposed to be involved in pain transmis-
sion and sensation in small fiber neuropathies.57,58
The main goal of the present study was to examine
and characterize the DRG neurons of FD mice model in
comparison to WT group in order to provide evidence
consistent with an overexpression of ion channels that
directly link the Gb3 accumulation in peripheral sensory
neurons and pain in FD. In this context, our previous
results have demonstrated an elevated expression of
Nav1.8 and TRPV1, but not TRPM8, in the epidermis
of a-GalA(/0) males glabrous skin of frontal paws in
comparison to control WT group.13 In addition, the
expression of the neuronal marker PGP9.5 specific for
neuronal terminations in the skin showed a significantly
decreased and scattered pattern of neuronal terminations
in a-GalA(/0) males as was previously observed in
human skin.13,31,59
To support the observation that pain sensitivity in a-
GalA(/0) males was due to ion channels alterations in
the expression, distribution, and function, we first
employed immunohistochemistry for detection of these
channels protein previously described in glabrous skin of
mice frontal paws.13 The immunostaining and protein
quantification using the TRPV1 antibody, in in vitro
cell cultures of DRG neurons and in cryosections of
whole DRGs, indicate an increased expression of recep-
tor directly in the DRG of a-GalA(/0) males compared
with DRG of a-GalA(þ/0) males. On the other hand, no
significant differences in TRPM8 and Nav1.8 expression
were observed in a-GalA(/0) mice compared with con-
trols. Our experimental evidences support the hypothesis
that the overexpression of TRPV1 channels observed in
the Fabry model generates alterations in action potential
generation and propagation resulting in producing pain.
The functional evaluation of TRPV1 in the native neur-
onal systems revealed a capsaicin activation more pro-
nounced in terms of total current and current density of
the a-GalA(/0) DRG neurons compared with WT
DRG neurons. A consequence of the higher TRPV1
activity in a-GalA(/0) sensory neurons is that these
mice exhibit a higher thermal sensitivity than WT litter-
mates, as evidenced from the shorter latency times in the
hot plate test. Here, we hypothesized that the increased
thermal nociception in a-GalA(/0) mice may result, at
least in part, from an augmented expression of TRPV1 in
the DRGs peripheral terminals.13 Noteworthy, blocking
of neuronal exocytosis with compound DD04107, which
inhibits the exocytotic recruitment of TRPV1 channels to
the neuronal surface in peptidergic nociceptors21,37,38
resulted in a significant attenuation of thermal sensitivity
in a-GalA(/0) mice, consistent with the tenet that the
enhanced thermal nociception of the a-GalA(/0) mice
may be due to an increased membrane recruitment of
TRPV1 in nociceptors. Although the susceptibility of
the thermal nociception of a-GalA(/0) mice to peptide
DD04107 suggests that the thermal hypersensitivity of a-
GalA(/0) mice may be due to an augmented surface
expression of TRPV1 in a-GalA(/0) nociceptors, add-
itional experiments are needed to demonstrate that an
enhanced membrane translocation of TRPV1 pivotally
contributes to the pain phenotype in FD patients.
Nonetheless, it is worth noting that the in vivo anti-noci-
ceptive activity of peptide DD04107 in a-GalA(/0)
mice implies a potential novel therapeutic strategy to
reduce the pain sensitivity in FD patients.
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Supplementary Fig. S1. Characterization of Capsaicin evoked ionic currents in DRG neurons of WT and a-GalA KO in cell culture.
(a) Quantitative representation of TRPV1 Capsaicin activated DRG neurons – the percentage of all DRG neurons responding to 1mM
Capsaicin stimuli was lower in a-Gal A(/0) (35%) in comparison to its WT control (60%). The activation of TRPV1 currents is significantly
diminished in a-Gal A(/0) DRG neurons in comparison to WT. (b) Capacitance of Capsaicin responding cells – the DRG neurons
responding to 1 mM Capsaicin stimuli by activation of inward cationic currents showed no differences between a-Gal A(/0) and a-Gal
A(+/0) mice. (c) Quantitative representation of TRPV1 currents recorded at 60 mV during the time window of 72 hours. Values are given
as means SE; WT (n24¼ 6; n48¼ 9; n72¼ 5) and KO (n24¼ 3; n48¼ 7; n72¼ 2). (d) Quantitative assessment of TRPV1 currents density by
normalization of peak current recorded at 60 mV to the capacitance of each cell. Values are given as means SE; WT (n24¼ 6; n48¼ 9;
n72¼ 5) and KO (n24¼ 3; n48¼ 7; n72¼ 2).
Supplementary Fig. S2. Long-term decrease in thermal sensitivity. (a) The statistically significant reduction in latency time of male KO
group after administration of saline demonstrates higher acute sensitivity to noxious hot thermal stimulation than in male WT group after
administration of saline (p< 0.05, n¼ 14 animals for WT, n¼ 14 animals for KO). (b) The subcutaneous administration of 3 mg/kg
DD04107 peptide significantly reduced the thermal hypersensitivity produced in the a-Gal A (/0) mouse model of FD (n¼ 15) by hot-
plate stimulus of 52C 0.1C in comparison to a-Gal A (/0) KO mice injected with saline (n¼ 14) in different time points within 24
hours after the injection. Two-way ANOVA followed by Fisher’s LSD post hoc test revealed that the peptide attenuated thermal
nociception up to 24 hours post-administration (Genotype effect x Time x Treatment effect F(6, 324)¼ 4.38, p¼ 0.0002).
16 Molecular Pain
